| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Intellia Therapeutics, Inc. (NTLA) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 21 sells. NTLA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.01M | $15.88M | - | |
| Dir | 207.5K | $3.25M | - | |
| Dir | 134.7K | $2.11M | - | |
| VP | 121.2K | $1.90M | - | |
| VP | 101.5K | $1.59M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 16, 2018 | Formela Jean Francois70 | Director | Sell | 6,686 | $25.04 | $167,389.36 | -100% | |
| May 14, 2018 | Leonard John M.83 | President And CEO | Sell | 8,400 | $24.00 | $201,600.00 | -100% | |
| Mar 20, 2018 | Formela Jean Francois70 | Director | Sell | 39,245 | $23.87 | $936,742.63 | -51.7% | |
| Jan 29, 2018 | Caribou Biosciences, Inc. | 10% Owner | Sell | 550,645 | $26.78 | $14,746,273.10 | -12.1% | |
| Dec 8, 2017 | Bermingham Nessan | President &CEO | Sell | 336,783 | $20.78 | $7,000,019.24 | -10.2% | |
| Sep 13, 2017 | Caribou Biosciences, Inc. | 10% Owner | Sell | 1,048,846 | $0.00 | - | -18.7% | |
| Jul 11, 2017 | Formela Jean Francois70 | Director | Sell | 150,000 | $16.24 | $2,435,440.00 | -1.4% | |
| Jul 11, 2017 | Atlas Venture Fund Ix, L.P. | 10% Owner | Sell | 150,000 | $16.24 | $2,435,440.00 | -1.4% | |
| Mar 10, 2017 | Formela Jean Francois70 | Director | Sell | 21,132 | $13.91 | $293,842.63 | -79.3% | |
| Mar 10, 2017 | Atlas Venture Associates Ix, L.P. | 10% Owner | Sell | 21,132 | $13.91 | $293,842.63 | -79.3% |